The Financial Horizons
No Result
View All Result
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Latest News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Latest News
No Result
View All Result
The Financial Horizons
No Result
View All Result
Home Editor's Pick

FET, INJ soar up to 20% as Injective announces plans to collaborate with Fetch.ai

by
June 25, 2024
in Editor's Pick
0
FET, INJ soar up to 20% as Injective announces plans to collaborate with Fetch.ai
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Fetch.ai (FET) and Injective (INJ) defied the current bearish markets with significant price increases over the past day.

Monday’s X post from Injective about “something brewing” with Fetch.ai catalyzed recoveries for the altcoins within the last 24 hours.

Something is brewing…$FET $INJ pic.twitter.com/mQdYoZIIfT

— Injective 🥷 (@injective) June 24, 2024

Injective’s post feature the company’s logos with a wavy line connecting them. That indicates an exchange of data between the duo.

Despite the few details, crypto enthusiasts interpreted the image as signaling a strategic partnership between Injective and Fetch.ai.

Market response

While the community awaits further details on the planned alliance, Injective’s post attracted speculations.

The development comes as players await the upcoming merger between Fetch.ai, Ocean Protocol, and SingularityNET, into the ASI token.

One player questioned whether FET developers have shifted from the anticipated ASI token merger and opted to work with Injective.

OMG $fet team had change of heart and is merging with $inj instead of the other two 😵😵

— Pinkee (@ordinary_Dave_K) June 24, 2024

FET and INJ’s current price actions

The speculations that emerged saw the associated tokens recovering from Monday’s slump.

FET climbed to $1.70 from $1.42 following the Injective’s post, gaining 19.72% on its daily chart.

Fetch.ai traded at $1.67 at press time, with daily trading volume up 85% to $282.5 million.

Altcoin INJ displayed a similar performance as it gained 14.59% over the last 24 hours to trade at $23.11 during this writing.

FET & INJ 1D Charts on Coinmarketcap

Besides the Injective-induced recovery, AI-related tokens such as AGIX, ARKM, and OCEAN recorded bullish moves over the past week.

AGIX gained 37% on its 7-day chart, while ARKM and OCEAN soared 28% and 35% in that timeframe.

The performance likely drew attention as the broad market recorded losses over the last seven days.

Bitcoin and Ethereum dropped 6.5% and 1.25% in the past week.

AGIX, FET, and OCEAN have stayed on the investor radar due to the upcoming merger, potentially contributing to their upside stance.

The trio looks ready to maintain robust momentum in the upcoming sessions.

Analyst Posty displayed confidence in FET’s recovery as “the chart isn’t looking too bad.”

$FET

Can’t believe I’m saying this but the chart isn’t looking too bad here…

Yesterday we seen a higher low form and now the question is, can we follow up with a higher high?

Currently facing local resistance at $1.70. From here to $1.95 it’s a bit of an ugly zone but it’s a… pic.twitter.com/x0lYNwBFiN

— Posty (@PostyXBT) June 25, 2024

Fetch.ai printed a higher low, and Posty expects a smooth sail toward $1.95 if FET overcomes the resistance zone at $1.70.

Further, Injective’s staking data shows confidence about the altcoin’s future performance.

Over 58M $INJ staked!!!

A clear fact that we are not playing here at @injective

🥷. pic.twitter.com/EqjWdWjRI3

— John Innocent 🥷 (@SacrosancCrypto) June 23, 2024

INJ investors have staked more than 58.44 million tokens, painting an optimistic picture for the token.

Bitcoin’s recovery from its current downbeat mood will boost FET and INJ’s revivals to record highs.

The post FET, INJ soar up to 20% as Injective announces plans to collaborate with Fetch.ai appeared first on Invezz

Previous Post

SolarEdge stock plunge: Bargain buy or falling knife?

Next Post

Novo Nordisk wins approval for its weight-loss drug from China

Next Post
Novo Nordisk wins approval for its weight-loss drug from China

Novo Nordisk wins approval for its weight-loss drug from China

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    Ex-White House officials to testify on who ‘really ran the country’ during Biden era

    Ex-White House officials to testify on who ‘really ran the country’ during Biden era

    June 17, 2025
    Blistering report calls for investigation into 5 ‘woke’ hospitals pushing ‘radical’ agenda with taxpayer money

    Blistering report calls for investigation into 5 ‘woke’ hospitals pushing ‘radical’ agenda with taxpayer money

    June 17, 2025
    Trump-branded wireless service launches — with a gold phone

    Trump-branded wireless service launches — with a gold phone

    June 17, 2025
    Reagan-nominated federal judge accuses Trump admin of ‘discrimination’ with cuts to NIH diversity grants

    Reagan-nominated federal judge accuses Trump admin of ‘discrimination’ with cuts to NIH diversity grants

    June 17, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: Thefinancialhorizons.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thefinancialhorizons.com | All Rights Reserved

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Editor’s Pick
    • Latest News

    Disclaimer: Thefinancialhorizons.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thefinancialhorizons.com | All Rights Reserved